Immunocine Cancer Center Opens Second Treatment Location in Cabo San Lucas

Responding to a growing number of patients seeking personalized cancer immunotherapy, Immunocine Cancer Center has opened a second treatment location in ...

August 20, 2026 | Thursday | News
Radiopharm Theranostics Schedules FDA Meeting for RAD101 Phase 3 Trial

RAD 101 Phase 2b trial demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint End-of-Phase 2 m...

August 19, 2026 | Wednesday | News
Evaxion Expands Cancer Vaccine Pipeline with EVX-05 for Glioblastoma

EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens...

August 19, 2026 | Wednesday | News
HUTCHMED Reports Positive Phase III Results for ORPATHYS Plus TAGRISSO in EGFR-Mutated NSCLC

HUTCHMED (China) Limited announces that positive high-level results from the SAFFRON Phase III trial showed ORPATHYS® (savolitinib) plus TAGRISSO®...

August 18, 2026 | Tuesday | News
SGPCR Institute Awards $6.7M to Advance Pancreatic Cancer Research

The Stephenson Global Pancreatic Cancer Research Institute (SGPCRI) announced the recipients of the 2026 Stephenson Global Scholar Grants. In partnership...

August 12, 2026 | Wednesday | News
Biogen Completes Acquisition of RayThera to Strengthen Immunology Pipeline

Biogen Inc. announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing sm...

August 10, 2026 | Monday | News
Leads Biolabs Advances Phase II Study of Opamtistomig Combination Therapy for First-Line Liver Cancer

Nanjing Leads Biolabs Co., Ltd. announced that its Phase II clinical study evaluating Opamtistomig (LBL-024), a proprietary PD-L1/4-1BB bispecific antibo...

August 07, 2026 | Friday | News
Beyond Checkpoint Inhibitors: Ernexa Therapeutics on ERNA-101's Novel Cell Therapy Approach

Immunologically "cold" tumors remain one of the greatest challenges in oncology, limiting the effectiveness of checkpoint inhibitors in cancers such as pla...

August 06, 2026 | Thursday | Interview
Delivering Genetic Medicines Where They Matter Most

Targeted genetic medicines are reshaping the future of cancer treatment by improving the precision of therapeutic delivery while addressing the challenges ...

August 03, 2026 | Monday | Expert Opinion
Verastem Oncology Dosed First Patient in Phase 2 TARGET-D 203 Trial of VS-7375 for Metastatic Colorectal Cancer

TARGET-D 203 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab or panitumumab in previously treated metastatic colorectal...

July 30, 2026 | Thursday | News
Massive Bio Partnered with GELL to Advance AI-Driven Oncology Research Across Latin America and the U.S.

-Massive Bio, a global leader in artificial intelligence-driven solutions for oncology, clinical trial matching, and patient navigation, and the Latin Am...

July 29, 2026 | Wednesday | News
Accord BioPharma Launches Interchangeable Denosumab Biosimilars OSVYRTI and JUBEREQ in the U.S.

Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology and c...

July 27, 2026 | Monday | News
Arcus Biosciences and AVEO Partner to Evaluate Casdatifan Plus Tivozanib in Kidney Cancer Study

  This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib a...

July 24, 2026 | Friday | News
Bayer and Henry Ford Health Partner to Expand Patient Access to Clinical Trials

Bayer, a global life sciences company, and Henry Ford Health announced a strategic partnership to expand clinical trial opportunities for patients. The w...

July 20, 2026 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close